Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.

Cancer science - 1 Jul 2016

Takashina Taichi, Kinoshita Ichiro, Kikuchi Junko, Shimizu Yasushi, Sakakibara-Konishi Jun, Oizumi Satoshi, Nishimura Masaharu, Dosaka-Akita Hirotoshi

Abstract excerpt

Recent discoveries have revealed that human cancer involves aberrant epigenetic alterations. We and others have previously shown that the histone methyltransferase EZH2, the catalytic subunit of polycomb repressive complex 2 (PRC2), is frequently overexpressed in non-small-cell lung cancer (NSCLC) and that an EZH2 inhibitor, 3-deazaneplanocin A, inhibits the proliferation of NSCLC cells. Transcriptional silencing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine
Share to Cyclin A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase Inhibitor p27

Share to Enhancer of Zeste Homolog 2 Protein

Share to Histone Deacetylase Inhibitors

Share to Hydroxamic Acids

Share to Polycomb Repressive Complex 2

Share to Vorinostat

Source

Open in PubMed Open full text

Identifiers

PMID: 27116120
DOI: 10.1111/cas.12957
PMCID: PMC4946723

Genes

EGFR
EED

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.PMID 27116120Read ↗

EZH2/G9a interact to mediate drug resistance in non-small-cell lung cancer by regulating the SMAD4/ERK/c-Myc signaling axisSemantic proximity Read ↗

PRC2 loss impairs small cell lung cancer tumorigenesis and enhances sensitivity to G9a/GLP inhibitionSemantic proximity Read ↗

Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma CellsSemantic proximity Read ↗

Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effectsSemantic proximity Read ↗

Targeting of cancer stem cells by inhibitors of DNA and histone methylationSemantic proximity Read ↗

Ezh2 Inhibitors Reverse Resistance to Gefitinib in Primary Egfr Wild-type Lung Cancer CellsSemantic proximity Read ↗

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.Semantic proximity Read ↗

Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cellsSemantic proximity Read ↗

Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma TherapySemantic proximity Read ↗

Novel HDAC11 inhibitors suppress lung adenocarcinoma stem cell self-renewal and overcome drug resistance by suppressing Sox2Semantic proximity Read ↗

Clinicopathological significance and prognostic role of EZH2 expression in non-small cell lung cancerSemantic proximity Read ↗

Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.